Biomadvanced Diagnostics

Biomadvanced Diagnostics, founded in 2021, is a medical technology company operating in the diagnostic equipment sector. The firm originated as a spin-off from the CR2TI research center and the University Hospital of Nantes, leveraging 20 years of translational research in immunology. The company was co-founded by Frédéric Pette (CEO), Jean-Michel BOULER (Chief Prospective Officer), Richard Danger (Chief Technology Advisor), and Sophie Brouard. This venture aims to address the critical need for improved monitoring of organ transplant recipients.

The company focuses on developing molecular diagnostic and biomarker tests to monitor the immune response in patients, particularly those who have undergone kidney or lung transplants. Its primary offering is a test that provides predictive scores and identifies biomarkers to assess the risk of transplant rejection. This enables clinicians to anticipate potential complications and tailor patient treatments more effectively, reducing the reliance on invasive, risky, and costly biopsy procedures. The technology is based on measuring gene expression through qPCR combined with an algorithm to produce a composite score, delivered via a physical analysis kit and access to a cloud-based server for data interpretation.

Biomadvanced Diagnostics' business model centers on the sale of these 'hybrid' diagnostic kits to healthcare providers. The company serves clinicians and hospitals, aiming to integrate its tests into standard diagnostic and treatment protocols. To advance its product development, the company has secured significant funding, including a €1.7 million seed round in September 2022 and subsequent financing totaling $2.4 million by July 2023. These funds are allocated to finalizing product design and conducting clinical studies, with a market launch anticipated for 2025. The initial clinical trials, including one for kidney transplant rejection, are in partnership with university hospitals in Nantes, Oslo, and Barcelona.

Keywords: molecular diagnostics, transplant rejection, biomarker tests, personalized medicine, kidney transplant, lung transplant, immune response monitoring, MedTech, qPCR, diagnostic equipment, predictive diagnostics, non-invasive testing, organ transplantation, clinical diagnostics, health technology, immunology, gene expression analysis, translational research, clinical trials, venture capital-backed